Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen keeps Kineret

Executive Summary

Amgen will keep IL-1 inhibitor Kineret (anakinra) for treatment of rheumatoid arthritis under a proposed consent agreement between Amgen and Federal Trade Commission that would allow the company's proposed acquisition of Immunex to proceed. FTC's July 12 announcement of the agreement notes that Kineret has had sales in excess of $2.4 mil. since its launch in November. The agreement would require the company to divest one of Immunex' marketed products, the neutrophil regeneration factor Leukine (sargramostim) (1"The Pink Sheet" Dec. 24, 2001, p. 16)...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts